Together we innovate

Our Immunology Innovation Program (IIP) is a core business strategy – collaboration with our academic and scientific partners ignites this discovery engine, identifying novel targets and building new antibody-based potential treatment options for patients.

Every candidate from our wholly owned and partnered pipelines has emerged from an IIP collaboration.

Antibody engineering

At the molecular level, we innovate at both the V region (where antigens and foreign proteins are recognized) and the Fc region (where antibodies modulate other cells in the immune system).



Fc, fragment crystallizable; V, variable.

argenx
MEDICAL AFFAIRS

Thank you for connecting with argenx.

Our innovation is powered by partnership – let's collaborate on the next generation of immunology therapies.

Learn more at **argenx.com/innovation** or by scanning the QR code

Inquiries and research proposals that are not Externally Sponsored Research can be sent to **BD@argenx.com**

argenx
MEDICAL AFFAIRS

The science of collaboration

Together we are better

MED-US-NON-2500099 v1 | August 2025

Together we discover

At argenx, our ethos is collaboration – where pioneering scientists and antibody engineers work side by side to accelerate the discovery of novel targets, disease pathways and differentiated medicines.

Our pipeline starts with strong science; aimed at translating immunology breakthroughs into differentiated medicines.

argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options.

Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others.

Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them.

*We know that **together we are better.***

The infinity sign symbolizes our commitment to science and patients; it has no bounds.

Learn more about our commitment to patients with autoimmune diseases by scanning the QR code

Together we make breakthroughs

Investigational molecules

ARGX-113
was designed as a human IgG1 antibody Fc-fragment and engineered for affinity to the neonatal Fc receptor (FcRn). FcRn is known to extend the half-life and availability of pathogenic IgG antibodies

- *ARGX-113 was built in collaboration with Prof. E. Sally Ward, PhD, who is a pioneer of FcRn biology*

ARGX-118
was designed as a highly differentiated antibody against Galectin-10, which is implicated in severe asthma and the persistence of mucus plugs

- *ARGX-118 was built in collaboration with Prof. Bart Lambrecht, MD, PhD, who identified a novel airway inflammation target – the first in decades*

ARGX-117
is a humanized IgG1 complement-inhibiting antibody targeting C2 under investigation in several complement-mediated autoimmune conditions

- *ARGX-117 was built in collaboration with Prof. C. Erik Hack, MD, PhD, a leader in the field of monoclonal antibodies for the treatment of coagulation and inflammatory disorders*

C, complement component; Fc, fragment crystallizable;
FcRn, neonatal fragment crystallizable receptor; Ig, immunoglobulin.

Together we push boundaries

Our partnered programs build on discoveries from the Immunology Innovation Program, enabling promising antibody assets to advance through collaboration with development partners:

ARGX-112 (now LEO 138559)
was designed as a SIMPLE Antibody™ to block the cytokine receptor of interleukin-22 and is now being evaluated by **LEO Pharma** for atopic dermatitis

ARGX-114 (now AGMB-101)
is an HGF-mimetic antibody agonist directed at the MET receptor, developed using SIMPLE Antibody™ technology. It is now in development by **AgomAb Therapeutics** for fibrotic, inflammatory, autoimmune and degenerative diseases

ARGX-115 (now ABBV-151)
was designed as a humanized monoclonal SIMPLE Antibody™ inhibitor of GARP-TGF-β1 and is being investigated by **AbbVie**. ARGX-115 is designed to block GARP and to reactivate the immune system against tumors

GARP, glycoprotein-A repetitions predominant protein;
HGF, hepatocyte growth factor;
MET, mesenchymal–epithelial transition;
TGF-β1, transforming growth factor-β1.

Together we fuel progress

At argenx, we believe that bringing solutions to patients should include accelerated discovery processes centered around innovative and collaborative science-driven research.

We support externally sponsored research through two key pathways:

Investigator-initiated studies
Research led by independent investigators who take full regulatory and legal responsibility for their studies. These may be interventional or observational. We provide support to help advance their goals

Clinical research collaborations
While also investigator-led, these studies allow for a more collaborative approach. We may propose or co-develop study concepts with researchers to explore innovative designs and push the science forward

Externally sponsored research can lead to meaningful advances in disease understanding and treatment.

Email **esr@argenx.com** to learn more about how you can get involved in externally sponsored research with argenx.

Together we advance patient care

We have the privilege of working alongside a number of academic collaborators – working together to accelerate discovery and advance patient care:

Bern University
Columbia University
Institut de Duve
Leiden University
Ludwig Cancer Research
National Jewish Health
Université Catholique de Louvain
Turin University
University of Pennsylvania
NYU School of Medicine
UT Southwestern
Flemish Institute for Biotechnology
Utrecht University